Adicet Bio, Inc. Payments of Debt Issuance Costs
Adicet Bio, Inc. (ACET) reported Payments of Debt Issuance Costs of $22.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2026-08-05
- Adicet Bio, Inc. payments of debt issuance costs for the quarter ending 2023-12-31 was $0.00.
- Adicet Bio, Inc. payments of debt issuance costs for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Adicet Bio, Inc. payments of debt issuance costs for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- Adicet Bio, Inc. payments of debt issuance costs for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- Adicet Bio, Inc. payments of debt issuance costs for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Adicet Bio, Inc. payments of debt issuance costs for fiscal 2022 was $364.00K, a 39.46% increase from fiscal 2021.
- Adicet Bio, Inc. payments of debt issuance costs for fiscal 2021 was $261.00K, a 66.24% increase from fiscal 2020.
- Adicet Bio, Inc. payments of debt issuance costs for fiscal 2020 was $157.00K.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $22.00K 10-Q · filed 2026-08-05 | |||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-05 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $0.00 derived: sum of 2 quarters · filed 2024-03-19 | $0.00 derived: sum of 3 quarters · filed 2024-03-19 | $0.00 10-K · filed 2024-03-19 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $0.00 10-Q · filed 2023-11-08 | -$1.00K derived: sum of 4 quarters · filed 2024-03-19 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $0.00 10-Q · filed 2023-08-09 | -$1.00K derived: sum of 3 quarters · filed 2024-03-19 | $19.00K derived: sum of 4 quarters · filed 2024-03-19 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 | -$1.00K derived: sum of 2 quarters · filed 2024-03-19 | $19.00K derived: sum of 3 quarters · filed 2024-03-19 | $242.00K derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $19.00K derived: sum of 2 quarters · filed 2024-03-19 | $242.00K derived: sum of 3 quarters · filed 2024-03-19 | $364.00K 10-K · filed 2024-03-19 |
| 2022-09-30 | $20.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $243.00K derived: sum of 2 quarters · filed 2023-11-08 | $365.00K 10-Q · filed 2023-11-08 | $472.00K derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $223.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $345.00K 10-Q · filed 2023-08-09 | $452.00K derived: sum of 3 quarters · filed 2023-08-09 | $457.00K derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $122.00K 10-Q · filed 2023-05-09 | $229.00K derived: sum of 2 quarters · filed 2023-05-09 | $234.00K derived: sum of 3 quarters · filed 2023-05-09 | $226.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $107.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $112.00K derived: sum of 2 quarters · filed 2023-03-15 | $104.00K derived: sum of 3 quarters · filed 2023-03-15 | $261.00K 10-K · filed 2023-03-15 |
| 2021-09-30 | $5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$3.00K derived: sum of 2 quarters · filed 2022-11-08 | $154.00K 10-Q · filed 2022-11-08 | $154.00K derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$8.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $149.00K 10-Q · filed 2022-08-10 | $149.00K derived: sum of 3 quarters · filed 2022-08-10 | $149.00K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $157.00K 10-Q · filed 2022-05-12 | $157.00K derived: sum of 2 quarters · filed 2022-05-12 | $157.00K derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $0.00 derived: sum of 2 quarters · filed 2022-03-15 | $157.00K 10-K · filed 2022-03-15 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $157.00K 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $157.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |